Early Registration & Domestic Chinese Company Rates Available

Register by May 25 to take advantge of early registration discounts.

• Registration for China-based Companies
• Registration for International Companies

Keynote Presentations

Continuous Bioprocessing for Production of Recombinant Proteins and Monoclonal Antibodies
Weichang Zhou, Ph.D., Senior Director, Commercial Cell Culture Development, Genzyme, a Sanofi Company

Comparability vs Similarity for Biosimilarity Assessment - Challenges and Opportunities in US FDA Biosimilar Guidance
Earl Dye, Ph.D., Director, Technical Regulatory Policy & Strategy, Genentech Inc.

Opportunities and Challenges for the Development of Biosimilar Monoclonal Antibodies in Europe
Sandy Eisen, M.D., MA FRCS, Dip Pharm Med, Chief Medical Officer, Frontline Pharma Consulting Ltd., United Kingdom

LinkedIn Groups

Join the BioProcessing Professionals LinkedIn Group

Join the China Life Sciences Network LinkedIn Group

At IBC's 4th Annual BioProcess International™ China event, the goal is to bring China and the rest of the world together to explore the missing gaps in China's development, and to help bring China up-to-speed on critical areas such as cell line engineering, media development, analytical characterization strategies to establish similarity between a biosimilar and its originator drug, as well as design of multi-product facilities and implementation of single-use systems.

Bringing together global leaders to provide you with proven scientific and technical strategies and innovations on:

• Cell Line Engineering, Cell Culture and Media Development
• Analytical Characterization, Comparability and Quality Assessment
• Downstream Processing and Viral Safety
• Single-Use Systems and Multi-Product Facilities
• Biosimilars Development - Regulatory and Market Challenges

Delivering you so much MORE in just 2 days...

• Experts from US and Europe with proven success stories
• Access to international service providers
• Facilitated networking
• Tactical strategies for informed decision making

New This Year! Hear from:

• Pfizer who will explore innovative solutions to streamline cell culture development platform process
• Henlius Biopharmaceuticals who will share their strategy from cell line development to filing IND for a biosimilar in less than 2 years
• Genentech who will take on comparability assessment for clinical development and post-approval CMC changes
• Novartis who will compare HPLC, CE, Mass Spec., NMR and other analytical technologies in the characterization of biological products
• Phage Pharmaceuticals who will detail the design of a multi-product, multi-phases, and multi-users cGMP facility
• Biocon India who will outline their low risk, flexible plant approach using single-use systems

Don't miss this opportunity to witness and partake in China's phenomenal growth! Get insider information and proven strategies to help increase your yield, improve your quality while ensuring efficiency of production and reducing manufacturing cost.

Why You Should Attend:

International companies:
This is your chance to meet and network with domestic Chinese/Asian drug developers, contract manufacturers and understand where they are in the area of processing capabilities, as well as find potential business partners and collaborators to develop biosimilars, biobetters or novel biologics.

China-based companies:
This is your opportunity to learn technical know-how and practical solutions from the experienced scientists and engineers from around the world, as well as hear how to trouble-shoot problems and avoid pitfalls in the quest for higher yield and better quality.

Your Global Industry Resource

Join the Fastest Growing Event Series for Bioprocess Scientists and Engineers

	August 21-22, 2012 Shanghai, China			October 8-12, 2012 Rhode Island, USA			April 17-18, 2013 Düsseldorf, Germany
www.IBCLifeSciences.com/BPIChina			www.IBCLifeSciences.com/BPI			www.bpi-eu.com